FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma By Ogkologos - October 27, 2025 181 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Acalabrutinib with Venetoclax for CLL or SLL No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Generic Eribulin January 12, 2024 FDA Amends Approval of Pembrolizumab to Treat Stomach and Esophageal Junction... November 17, 2023 Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment... September 3, 2025 Breaking down the new standards for cancer care proposed by NHS... March 11, 2022 Load more HOT NEWS Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL Multipronged Approach Eliminates Racial Disparities in Early-Stage Lung Cancer Treatment Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma... Updated Nutrition Facts Label Reflects Science on Diet and Health, including...
